| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/09/2003 | WO2002031142A3 Antisense nucleic acid against alphav integrin |
| 01/09/2003 | WO2002026997A3 Dsp-16 dual-specificity phosphatase |
| 01/09/2003 | WO2002014485A3 Kallikrein gene |
| 01/09/2003 | WO2002009716A3 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 01/09/2003 | WO2002000017A3 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/09/2003 | WO2001098351A3 G-protein coupled receptors |
| 01/09/2003 | WO2001097828A3 Rhob as a suppressor of cancer cell growth and cell transformation |
| 01/09/2003 | WO2001091740A3 Compositions containing naphthaquinone and an antiproliferative agent |
| 01/09/2003 | WO2001090390A9 Use of baculovirus vectors in gene therapy |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001072728B1 Novel piperazine derivatives |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | WO2001057267A9 Methods and materials relating to cub domain polypeptides and polynucleotides |
| 01/09/2003 | WO2001055336A9 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/09/2003 | WO2001055333A9 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides |
| 01/09/2003 | US20030009036 To produce polymers; cancer therapy |
| 01/09/2003 | US20030009033 Substituted condensation products of N-benzyl-3-indenylacent amides with heterocyclic aldehydes for neoplasia |
| 01/09/2003 | US20030009032 For inhibiting the replication or infectivity of a virus; therapy |
| 01/09/2003 | US20030008924 Providing cell which overexpresses a Bcl-2 family protein; gossypol compound; treating with cell with an effective amount of gossypol compound under conditions such that apoptosis in cell is modulated |
| 01/09/2003 | US20030008915 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 01/09/2003 | US20030008909 For therapy of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of endometrium, ovary, breast, colon, prostate, pituitary, meningioma and other hormone-dependent tumors |
| 01/09/2003 | US20030008908 Isoxazoline compounds having MIF antagonist activity |
| 01/09/2003 | US20030008906 Administering benzothiazole compound for therapy, prophylaxis of disease |
| 01/09/2003 | US20030008901 For therapy of arthritis, cancer, and other diseases characterized by matrix metalloproteinase or mammalian reprolysin activity |
| 01/09/2003 | US20030008898 Indole derivatives and their use for the treatment of malignant and other diseases based on pathological proliferation |
| 01/09/2003 | US20030008896 Isoquinolinone derivatives |
| 01/09/2003 | US20030008888 Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/09/2003 | US20030008881 Substituted phenylcyclohexanecarboxamides and their use |
| 01/09/2003 | US20030008873 For therapy of cancer |
| 01/09/2003 | US20030008872 2,3-Diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors |
| 01/09/2003 | US20030008866 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 01/09/2003 | US20030008862 Function as sulfatase and/or blocking estrogen receptors; prophylaxis and therapy |
| 01/09/2003 | US20030008850 For therapy and prophylaxis of cancer |
| 01/09/2003 | US20030008846 Use of dopamine receptor antagonists in palliative tumor therapy |
| 01/09/2003 | US20030008841 Anti-HCV nucleoside derivatives |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008809 Use of 5-HT (3) receptor antagonists for treating musculoeskeletal diseases |
| 01/09/2003 | US20030008399 Controlling viral replication or gene expression in a cell; obtain cell infected with virus, transform with nucleotide sequence expressng preferential replicases, monitor viral gene expression |
| 01/09/2003 | US20030008398 Nucleotide sequences coding polypeptide for use in the treatment of autoimmune and inflammatory diseases |
| 01/09/2003 | US20030008390 Genetically engineered cell for use in the generation of viral vector for use in gene therapy |
| 01/09/2003 | US20030008354 Peptide for use in the diagnosis and treatment of parkinson's, cancer and developmental defects |
| 01/09/2003 | US20030008349 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 01/09/2003 | US20030008338 Assay methods and kits therefor |
| 01/09/2003 | US20030008330 Nucleotide sequences coding polypeptides for use in the treatment and prevention of cancer and autoimmune disease |
| 01/09/2003 | US20030008293 Detection of polymorphism in preferential nucleotide sequences; obtain cells, extract nucleotide sequences, incubate with probe, detect signal, monitor hybridization pattern |
| 01/09/2003 | US20030008284 Polynucleotides related to colon cancer |
| 01/09/2003 | US20030008023 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 01/09/2003 | US20030008021 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/09/2003 | US20030008018 Acrochordon alleviation |
| 01/09/2003 | US20030007977 Vaccine containing amino acid |
| 01/09/2003 | US20030007976 Anticancer agents; sensitivity to Mycobacterium |
| 01/09/2003 | US20030007968 Administering bone marrow cells with lymphyocytes removed; then busulfan |
| 01/09/2003 | US20030007965 Treatment of substance P-related disorders |
| 01/09/2003 | US20030007928 Anticancer agent |
| 01/09/2003 | CA2490219A1 Fat-binding polymers |
| 01/09/2003 | CA2452364A1 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | CA2452202A1 Diagnostic methods and agents |
| 01/09/2003 | CA2452200A1 Method for identifying compounds that specifically deplete mast cells |
| 01/09/2003 | CA2452196A1 T cell regulatory genes and methods of use thereof |
| 01/09/2003 | CA2452192A1 Pyrido-pyrido-pyrrolo pyrrolo-indole and pyrido-pyrrolo pyrrolo carbazole derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 01/09/2003 | CA2452171A1 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| 01/09/2003 | CA2452094A1 Screening method for identifying cancer therapy-relevant compounds |
| 01/09/2003 | CA2452092A1 Carbohydrate derivatives |
| 01/09/2003 | CA2452082A1 Extracellular messengers |
| 01/09/2003 | CA2452058A1 Bispecific antibodies that bind to vegf receptors |
| 01/09/2003 | CA2452030A1 Sustained release pharmaceutical composition |
| 01/09/2003 | CA2451854A1 Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof |
| 01/09/2003 | CA2451846A1 Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome |
| 01/09/2003 | CA2451464A1 N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| 01/09/2003 | CA2451236A1 Peptides for use as translocation factors |
| 01/09/2003 | CA2451195A1 Antitumoral formulations of thioxanthenone |
| 01/09/2003 | CA2451128A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 01/09/2003 | CA2451039A1 Methods for preparation and use of 1.alpha.,24(s)-dihydroxyvitamin d2 |
| 01/09/2003 | CA2451037A1 Method of treating malignancy associated hypercalcemia using active vitamin d analogues |
| 01/09/2003 | CA2450722A1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 01/09/2003 | CA2450686A1 Substituted 8-arylquinoline pde4 inhibitors |
| 01/09/2003 | CA2450356A1 Bone anabolic compounds and methods of use |
| 01/09/2003 | CA2424645A1 New use of dipeptidyl peptidase iv inhibitors |
| 01/09/2003 | CA2420548A1 Composition comprising vitamin c and a pyrone or furanone compound |
| 01/09/2003 | CA2418543A1 New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| 01/08/2003 | EP1273918A2 Method of selecting evolved binding members using a native epitope |
| 01/08/2003 | EP1273667A1 High throughput identification of modulators of angiogenesis |
| 01/08/2003 | EP1273659A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/08/2003 | EP1273658A1 Novel protein, dna thereof and process for producing the same |
| 01/08/2003 | EP1273657A1 Novel protein, process for producing the same and use thereof |
| 01/08/2003 | EP1273656A1 Use of inhibitors of expression or activity of p8/com1 for treating tumours |
| 01/08/2003 | EP1273582A1 Heterocyclo-alkylsulfonyl pyrazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273580A1 Sulfonyl heteroaryl triazoles as anti-inflammatory and analgesic agents |
| 01/08/2003 | EP1273576A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/08/2003 | EP1273309A1 Gene therapeutic method for the treatment of GnRH-receptor positve carcinomas through GnRH induced tumor cell specific activation of a therapeutic gene, corresponding nucleic acids and vectors |
| 01/08/2003 | EP1273296A2 Combination chemotherapy |
| 01/08/2003 | EP1273289A1 Pharmaceutical compositions containing ascomycin derivatives |
| 01/08/2003 | EP1273288A1 Pharmaceutical compositions containing rapamycin derivatives |
| 01/08/2003 | EP1272853A2 Methods for identifying and using amyloid-inhibitory compounds |
| 01/08/2003 | EP1272670A2 Diagnosis of diseases associated with dna adducts |
| 01/08/2003 | EP1272665A1 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/08/2003 | EP1272653A2 Methods for ansamitocin production |
| 01/08/2003 | EP1272652A2 Herpes viruses for immune modulation |
| 01/08/2003 | EP1272647A1 Multivalent antibodies and uses therefor |
| 01/08/2003 | EP1272641A2 Serine-threonine kinase |